Antiretroviral‐Induced Toxicity in Umbilical Cord Blood‐Derived Haematopoietic Stem/Progenitor Cells
Open Access
- 27 April 2025
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (8)
Abstract
Improvements in administration and efficacy of antiretroviral therapy (ART) have reduced rates of mother‐to‐child transmission (MTCT) of human immunodeficiency virus (HIV) to < 2%. However, in utero exposure to antiretrovirals (ARVs) leads to abnormalities in HIV‐exposed uninfected (HEU) infants. We determined the effect of five ARVs on human umbilical cord blood (UCB)‐derived haematopoietic stem/progenitor cells (HSPC) with the aim of exploring a potential causal relationship with haematological abnormalities. Efavirenz (EFV) was cytotoxic to HSPCs alone and in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Dolutegravir (DTG) had a biphasic effect on HSPC expansion. Immunophenotypic analysis showed increased erythroid and granulocyte precursors after 7‐day culture with these drugs. Finally, using colony forming unit (CFU) assays, we observed impairment in the formation of CFU‐GEMM and CFU/Burst forming unit (BFU) erythroid (E) in the presence of DTG, lamivudine (3TC) and TDF, both visually and immunophenotypically. We conclude that multiple potential HSPC toxicities exist with ARVs commonly used in pregnancy, prompting the need for further research to confirm the safety of these drugs in this vulnerable group.Keywords
Funding Information
- Institute for Cellular and Molecular Medicine, University of Pretoria
- South African Medical Research Council
This publication has 54 references indexed in Scilit:
- Enhanced oxidative stress and increased mitochondrial mass during Efavirenz‐induced apoptosis in human hepatic cellsBritish Journal of Pharmacology, 2010
- Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected WomenAntimicrobial Agents and Chemotherapy, 2009
- Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infantsAIDS, 2008
- Hematologic Effects of Maternal Antiretroviral Therapy and Transmission Prophylaxis in HIV-1-Exposed Uninfected Newborn InfantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- HIV‐related neutropaenia exacerbated by efavirenzHIV Medicine, 2006
- Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA PolymeraseAntimicrobial Agents and Chemotherapy, 2004
- Lamivudine-induced pure red cell aplasiaAmerican Journal of Hematology, 2000
- Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV‐1 infected patientsBritish Journal of Clinical Pharmacology, 1999
- Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis BHepatology, 1997
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987